2020-10-24| Asia-PacificCOVID-19

Taiwanese Government Grants 16 Million to aid Adimmune’s COVID-19 Vaccine Trials

by Tyler Chen
Share To

By Tyler Chen

As the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia and the only PIC/S GMP manufacturer of human vaccines in Taiwan, Taiwan’s biotech company Adimmune Corporation lately acquired 458 million TWD (around 16 million USD) grant from the government to advance COVID-19 vaccine clinical trials.


AdimrSC-2f Under Phase 1 Trial

Adimmune’s self-developed vaccine AdimrSC-2f (SARS-COV-2) has entered Phase 1 clinical trial on August 24, and Phase 2 is expected to begin in November.

The study (NCT04522089) aims to investigate the safety and immunogenicity of AdimrSC-2f. Phase 1 of the trial includes 68 healthy subjects aged 20 to 60-year-old and breaking into 4 separate groups. Four groups will respectively be given a low, medium, high dose of AdimrSC-2f, while one group will receive a low dose of AdimrSC-2f with aluminum as an adjuvant. The trial is conducted under a randomized, single-centered setting at National Taiwan University Hospital.

If the result shows any promise, AdimrSC-2f will enter Phase 2 on November 20, enrolling at least 1,500 subjects cooperating with more hospitals. The overall study is estimated to complete on March 20, 2021.

To strengthen the manufacturing power, Adimmune, on June 9, announced the 700 million TWD investment (around 24 million USD) to expand a new production line to meet the surging needs for vaccines. The expansion is expected to complete in 2021.

Adimmune’s Partnership

Founded in 1965, Adimmune has worked with one of Japan’s largest vaccine researchers and manufacturers, Kitasato Daiichi Sankyo, obtaining the technology for tetanus vaccines, Japanese encephalitis vaccines, influenza vaccines, bird flu vaccines’ production. Moreover, Adimmune joined forces with Crucell N.V., which Johnson & Johnson acquired to establish Adimmune’s EU PIC/S GMP quality system.

Adimmune’s product line includes the Trivalent Influenza vaccine, the Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin.

Related Article: Taiwan’s TTY Biopharm Company Signs COVID-19 Vaccine Deal with BioNTech for 30 Million Doses




© All rights reserved. Collaborate with us:
Related Post
The U.S. COVID-19 Public Health Emergency Ends in May, but FDA’s EUA Authority Remains
Novavax Begins Phase 2 For COVID-19/Influenza Combination And Stand-Alone Flu Shots
Novavax Offers Up $125 Million Of Stock For COVID-19 Vaccine Launch
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
Ways to Reduce Carbon Emission in Cement Manufacturing
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
Scroll to Top